Compare MTRN & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRN | IMNM |
|---|---|---|
| Founded | 1931 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 2000 | 2020 |
| Metric | MTRN | IMNM |
|---|---|---|
| Price | $177.45 | $23.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $52.50 | $32.80 |
| AVG Volume (30 Days) | 164.6K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.31% | N/A |
| EPS Growth | ★ 1178.57 | 51.40 |
| EPS | ★ 3.58 | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $15.31 | N/A |
| Revenue Next Year | $7.57 | $1,127.34 |
| P/E Ratio | $50.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $70.94 | $7.15 |
| 52 Week High | $183.96 | $27.65 |
| Indicator | MTRN | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 68.01 | 60.06 |
| Support Level | $119.57 | $23.67 |
| Resistance Level | N/A | $25.30 |
| Average True Range (ATR) | 5.72 | 1.05 |
| MACD | 2.79 | 0.31 |
| Stochastic Oscillator | 81.65 | 72.58 |
Materion Corp specializes in the development of specialty engineered alloy systems, inorganic chemicals and powders, precious and non-precious metals, beryllium and beryllium composites, and precision filters and optical coatings. The company operates in four reportable segments: Performance Materials, Electronic Materials, Precision Optics, and Others. The majority of revenue is derived from Electronic Materials which produces chemicals, microelectronics packaging, precious metal, non-precious metal, and specialty metal products, including vapor deposition targets, frame lid assemblies, clad and precious metal pre-forms. The Performance Materials segment provides engineered solutions comprised of beryllium and non-beryllium-containing alloy systems and custom-engineered parts.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.